Cargando…
Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by immunohistochemistry in tumours of patients who took...
Autores principales: | Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360599/ https://www.ncbi.nlm.nih.gov/pubmed/17088909 http://dx.doi.org/10.1038/sj.bjc.6603449 |
Ejemplares similares
-
Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005) -
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
por: Gast, Marie-Christine W, et al.
Publicado: (2008) -
High-dose chemotherapy in breast cancer: Dutch randomized studies
por: Rodenhuis, S, et al.
Publicado: (2001) -
DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999) -
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
por: Vollebergh, M. A., et al.
Publicado: (2011)